Derivative works — US Patent 7704721

Defensive Disclosure: US Patent 7704721 Derivatives

This document outlines derivative compositions and methods based on US Patent 7704721, focusing on recombinant adeno-associated virus (rAAV) virion aggregation prevention. The intent is to establish prior art for foreseeable incremental improvements, thereby rendering them obvious or non-novel. The core inventive step, as described in independent Claim 1, involves:

Purifying rAAV virions from a lysate using ultracentrifugation and/or chromatography.
Adding one or more salts of multivalent ions (citrate, phosphate, sulfate, magnesium) to achieve an ionic strength of at least 200 mM.
Maintaining a rAAV concentration exceeding 1x10^13 vg/ml up to 6.4x10^13 vg/ml.
Maintaining a pH between 7.5 and 8.0.

Derivative variations explore alternative materials, extreme operational parameters, cross-domain applications, integration with emerging technologies, and inverse/failure modes, all with technical enabling descriptions and illustrative Mermaid diagrams.

Derivative Variations

1. Material & Component Substitution

Derivative 1.1: Alternative Multivalent Ions and Counterions

Enabling Description: The method utilizes alternative multivalent ions, specifically polyphosphate salts (e.g., sodium hexametaphosphate, potassium tripolyphosphate) or calcium acetate, to achieve an ionic strength of at least 250 mM. The polyphosphate salts are employed at concentrations ranging from 50 mM to 150 mM, while calcium acetate is used at 75 mM to 200 mM. The pH of the purified rAAV preparation is maintained at 7.8 ± 0.2 using a HEPES buffer system at 20 mM concentration, ensuring compatibility with the rAAV virion integrity. The purification steps remain as described in the parent patent, employing ultracentrifugation and/or chromatography to obtain purified virions at concentrations between 1x10^13 and 7.0x10^13 vg/mL. The addition of polyphosphate or calcium acetate salts is performed via diafiltration or direct addition with gentle mixing to achieve the target ionic strength and pH range.
```
graph TD
    A[rAAV Lysate] --> B{Purification: Ultracentrifugation/Chromatography}
    B --> C[Purified rAAV Virions (1e13-7e13 vg/mL)]
    C --> D{Addition of Alternative Multivalent Salts}
    D -- "Polyphosphate (50-150mM) OR Calcium Acetate (75-200mM)" --> E[High Ionic Strength rAAV Prep (>=250mM)]
    E -- "Buffer: 20mM HEPES, pH 7.8+/-0.2" --> F[Stable rAAV Formulation]
```

Derivative 1.2: Advanced Membrane Materials for Purification

Enabling Description: The purification of rAAV virions from the lysate is performed using tangential flow filtration (TFF) with hollow fiber membranes constructed from regenerated cellulose or polyethersulfone (PES) coated with hydrophilic polymers, having a nominal pore size of 100 kDa. This substitution aims to minimize non-specific binding and enhance recovery, particularly at high vector concentrations. Following purification, multivalent salts, such as zinc sulfate, are added at a concentration of 100 mM to 300 mM to achieve a bulk ionic strength of at least 300 mM. The pH is precisely controlled at 7.6 using a bicine buffer system (25 mM), maintaining the rAAV concentration within the specified range of 1x10^13 to 6.4x10^13 vg/mL. Surfactants like Polysorbate 20 at 0.01% (w/v) are also incorporated during the final formulation step to further reduce surface adsorption losses.
```
graph TD
    A[rAAV Lysate] --> B{TFF Purification: Regenerated Cellulose/PES Membrane (100 kDa)}
    B --> C[Purified rAAV Concentrate]
    C --> D{Addition: Zinc Sulfate (100-300mM)}
    D -- "Target Ionic Strength >=300mM" --> E[Formulation Buffer: 25mM Bicine, pH 7.6]
    E -- "Add: 0.01% Polysorbate 20" --> F[Stable rAAV Prep (1e13-6.4e13 vg/mL)]
```

2. Operational Parameter Expansion

Derivative 2.1: Ultra-High Concentration and Supercooling Storage

Enabling Description: Purified rAAV virions are concentrated to extreme levels, ranging from 7.0x10^13 vg/mL up to 1.0x10^15 vg/mL, by employing ultrafiltration/diafiltration with advanced low-binding membranes (e.g., ceramic membranes with 30 kDa cutoff). The formulation includes a combination of 150 mM sodium citrate and 50 mM magnesium sulfate, resulting in an ionic strength exceeding 700 mM. The pH is precisely controlled at 7.7. For extended storage, the preparation is supercooled to temperatures between -5°C and -15°C without freezing, by carefully controlling the cooling rate and potentially incorporating cryoprotectants like trehalose (up to 2% w/v) at sub-nucleating concentrations that do not significantly alter osmolarity or ionic strength. Dynamic light scattering (DLS) is continuously monitored during supercooling to detect incipient aggregation.
```
stateDiagram-v2
    [*] --> Lysate
    Lysate --> Purification: Ultracentrifugation/Chromatography
    Purification --> Concentration: UF/DF (7e13-1e15 vg/mL)
    Concentration --> Formulation: (150mM Citrate + 50mM MgSO4, pH 7.7, IS >700mM)
    Formulation --> Supercooling: (to -5C to -15C, w/ <2% Trehalose)
    Supercooling --> Monitoring: DLS
    Monitoring --> Stable_Storage
    Stable_Storage --> [*]
```

Derivative 2.2: Continuous Flow Purification and Formulation at Elevated Pressure

Enabling Description: rAAV virion purification and subsequent high ionic strength formulation are conducted within a continuous flow microfluidic system operating at elevated hydrostatic pressures (5-10 bar). Lysate is processed through serially connected microfluidic channels containing integrated chromatographic purification media (e.g., monoliths or packed beds of ion-exchange beads). Post-purification, a high-pressure injector introduces a concentrated solution of 200 mM dipotassium phosphate (yielding ~600 mM ionic strength) into the rAAV stream. The mixing chamber, also under elevated pressure, ensures rapid and homogenous distribution of the multivalent ions. The pH is maintained at 7.9 via an inline pH sensor and automated feedback control system. The entire process occurs at a flow rate optimized to minimize shear stress on virions while achieving target concentrations (1x10^13 to 6.4x10^13 vg/mL) and ionic strength.
```
graph TD
    A[rAAV Lysate] -- "Inlet Pressure 5-10 bar" --> B(Microfluidic Purification System)
    B -- "Continuous Flow" --> C[Purified rAAV Stream]
    D(Dipotassium Phosphate 200mM) -- "High Pressure Injector" --> C
    C --> E(High-Pressure Mixing Chamber)
    E -- "Inline pH Sensor" --> F{Automated pH Control (7.9)}
    F --> G[Stable rAAV Formulation Outlet]
```

Derivative 2.3: High-Frequency Acoustic Mixing for Excipient Addition

Enabling Description: Following conventional purification (ultracentrifugation or chromatography), rAAV virions are subjected to an excipient addition process utilizing high-frequency acoustic mixing (e.g., 500 kHz to 2 MHz) to rapidly and uniformly disperse multivalent ion salts. A concentrated stock of 150 mM magnesium citrate is added to the purified virions (at 2.0x10^13 vg/mL) within a specialized acoustic mixing chamber. The acoustic energy provides rapid, cavitation-free mixing, preventing localized concentration gradients that could induce transient aggregation. This results in a final ionic strength of approximately 450 mM. The pH is precisely maintained at 7.5 using a Tris-acetate buffer system. The process duration is minimized (e.g., <30 seconds) to prevent potential acoustic-induced virion damage.
```
sequenceDiagram
    participant L as rAAV Lysate
    participant P as Purification (UC/Chrom)
    participant V as Purified Virions (2e13 vg/mL)
    participant MC as Mg Citrate (150mM)
    participant AM as Acoustic Mixing Chamber
    participant B as Tris-Acetate Buffer
    participant F as Final Formulation

    L->P: Process lysate
    P->V: Obtain purified virions
    V->AM: Transfer virions
    MC->AM: Inject Mg Citrate
    B->AM: Add Tris-Acetate (pH 7.5)
    AM->AM: High-Frequency Acoustic Mixing (500kHz-2MHz)
    AM-->F: Release stable formulation (IS ~450mM)
```

3. Cross-Domain Application

Derivative 3.1: Stabilized Bacteriophages for Agricultural Biopesticides (AgTech)

Enabling Description: This method applies the high ionic strength stabilization principle to bacteriophages intended for use as agricultural biopesticides. Lysates containing specific bacteriophages (e.g., T4 phage targeting E. coli or phages against plant pathogens) are purified via ultrafiltration and anion-exchange chromatography to achieve a particle concentration of 1x10^12 to 5x10^13 PFU/mL. To this purified preparation, 120 mM potassium sulfate and 80 mM calcium phosphate salts are added, resulting in a total ionic strength of at least 350 mM. The pH is adjusted to 7.0 using a MOPS buffer system. This stabilized bacteriophage formulation is then sprayed onto crops or incorporated into irrigation systems to control bacterial infections, exhibiting enhanced shelf-life and efficacy under various environmental stresses compared to unstabilized preparations.
```
graph TD
    A[Bacteriophage Lysate (Ag)] --> B{Purification: UF/Anion-Exchange Chromatography}
    B --> C[Purified Bacteriophages (1e12-5e13 PFU/mL)]
    C --> D{Addition of Multivalent Salts (120mM K2SO4 + 80mM CaPO4)}
    D -- "Target Ionic Strength >=350mM" --> E[Formulation Buffer: MOPS pH 7.0]
    E --> F[Stable Biopesticide Formulation]
```

Derivative 3.2: Viral-Like Particle (VLP) Stabilization for Cosmetic Gene Delivery (Cosmetics)

Enabling Description: Viral-like particles (VLPs) engineered for topical gene delivery in cosmetic applications (e.g., carrying genes for collagen synthesis or antioxidant enzymes to skin cells) are produced in insect cell cultures and purified using sucrose density gradient ultracentrifugation and size-exclusion chromatography. The purified VLP preparation, with a concentration of 5x10^12 to 2x10^13 particles/mL, is then formulated with 100 mM disodium citrate and 30 mM magnesium chloride, achieving an ionic strength of approximately 400 mM. The pH is buffered to 8.0 using a Tris-HCl system. This formulation is incorporated into cosmetic creams or serums, providing enhanced stability of the VLPs against aggregation during storage and application, thereby preserving their integrity and transduction efficiency for cosmetic effects.
```
flowchart TD
    A[VLP Lysate (Cosmetics)] --> B(Purification: Sucrose Gradient UC + SEC)
    B --> C{Purified VLPs (5e12-2e13 particles/mL)}
    C --> D[Addition of Multivalent Salts (100mM Disodium Citrate + 30mM MgCl2)]
    D -- "Ionic Strength ~400mM" --> E(Buffer: Tris-HCl pH 8.0)
    E --> F[Stable VLP Cosmetic Formulation]
```

Derivative 3.3: Stabilization of Exosomes for Targeted Drug Delivery (Pharmaceuticals - non-viral)

Enabling Description: Exosomes, naturally derived nanovesicles used for targeted drug delivery (e.g., carrying small molecule drugs or therapeutic RNAs), are isolated from cell culture supernatant and purified by differential ultracentrifugation and asymmetric flow field-flow fractionation. The resulting purified exosome preparation, containing 1x10^11 to 5x10^12 particles/mL, is stabilized by the addition of 80 mM sodium pyrophosphate and 40 mM zinc acetate, achieving an ionic strength of at least 280 mM. The pH is adjusted to 7.2 using a phosphate-buffered saline (PBS) system. This formulation prevents exosome aggregation, maintaining their colloidal stability, cargo integrity, and targeting efficiency for intravenous administration or localized delivery, thus enhancing their therapeutic potential.
```
classDiagram
    class Exosome_Lysate {
        +source_cells
        +supernatant
    }
    class Purification {
        +Differential_UC
        +AF4_Fractionation
    }
    class Purified_Exosomes {
        +concentration: 1e11-5e12 particles/mL
        +integrity
    }
    class Multivalent_Salts {
        +Sodium_Pyrophosphate: 80mM
        +Zinc_Acetate: 40mM
        +Ionic_Strength: >=280mM
    }
    class Buffer_System {
        +PBS: pH 7.2
    }
    class Stable_Exosome_Formulation {
        +enhanced_stability
        +cargo_integrity
        +targeting_efficiency
    }

    Exosome_Lysate --> Purification
    Purification --> Purified_Exosomes
    Purified_Exosomes --> Multivalent_Salts
    Multivalent_Salts --> Buffer_System
    Buffer_System --> Stable_Exosome_Formulation
```

4. Integration with Emerging Tech

Derivative 4.1: AI-Driven Formulation Optimization with Real-time DLS

Enabling Description: A closed-loop system integrates an AI-driven optimization algorithm with real-time dynamic light scattering (DLS) measurements to dynamically adjust the concentration of multivalent ions during rAAV formulation. Purified rAAV virions are fed into a mixing manifold where stock solutions of sodium citrate and magnesium sulfate are introduced by automated syringe pumps. An inline DLS sensor continuously monitors the average particle radius (Rh) and polydispersity index (PDI). The AI algorithm, trained on historical aggregation data, predicts optimal salt concentrations to maintain Rh below 18 nm and PDI below 0.15, even as virion concentration increases towards 6.4x10^13 vg/mL. The algorithm then sends feedback to the syringe pumps to precisely adjust the inflow of salts, ensuring an ionic strength of at least 200 mM while minimizing total salt content for desired osmolarity, and maintaining pH at 7.7 ± 0.1.
```
flowchart LR
    A[Purified rAAV Virions] --> B(Mixing Manifold)
    C[Sodium Citrate Stock] --> B
    D[Magnesium Sulfate Stock] --> B
    B --> E(Inline DLS Sensor)
    E -- "Rh, PDI" --> F{AI Optimization Algorithm}
    F -- "Optimal Salt Conc." --> G[Automated Syringe Pumps]
    G --> C & D
    B --> H[Stable rAAV Formulation]
    H -- "pH 7.7+/-0.1" --> I[Storage/Dispensing]
```

Derivative 4.2: IoT-Enabled Environmental Monitoring for Cold Chain Stability

Enabling Description: rAAV preparations formulated with high ionic strength solutions (e.g., 100 mM sodium citrate, 10 mM Tris pH 8.0, 0.001% Pluronic F68, with ionic strength ~500 mM) are stored in containers equipped with embedded IoT sensors. These sensors continuously monitor critical environmental parameters such as temperature (-80°C to 4°C), relative humidity, and vibration, transmitting data to a cloud-based platform. The IoT system triggers alerts if parameters deviate from predefined stability ranges (e.g., temperature excursions that could lead to aggregation). Data analysis on the cloud platform correlates environmental conditions with batch-specific stability profiles (e.g., historical DLS data, infectivity titers), providing real-time risk assessment for each stored vial. This enables proactive intervention or re-testing of batches exposed to transient destabilizing conditions.
```
graph TD
    A[Stable rAAV Formulation (IS ~500mM)] --> B(IoT-Enabled Storage Container)
    B -- "Temp, Humidity, Vibration" --> C(IoT Sensors)
    C -- "Real-time Data (Wireless)" --> D(Cloud Platform)
    D -- "Data Analysis & Risk Assessment" --> E{Alert System / Proactive Intervention}
    E -- "User Notification" --> F[Operators / QA]
```

Derivative 4.3: Blockchain for Verifiable Supply Chain and Formulation Integrity

Enabling Description: A blockchain-based system is implemented to provide immutable records of each rAAV batch's purification, formulation, and storage conditions. Each significant step—from lysate processing, purification (e.g., ultracentrifugation, chromatography), addition of multivalent ions (e.g., 200 mM sodium phosphate to achieve an ionic strength of 600 mM at pH 7.5), concentration (e.g., 5.0x10^13 vg/mL), and pH adjustment—is logged as a transaction on a distributed ledger. Sensor data from environmental monitoring (as in Derivative 4.2) and quality control assays (e.g., DLS, infectivity titer) are cryptographically hashed and linked to the batch's unique ID on the blockchain. This provides a transparent, tamper-proof audit trail that verifies the adherence to critical parameters for preventing aggregation and ensures product integrity throughout its lifecycle, enhancing trust among stakeholders (manufacturers, distributors, clinics).
```
sequenceDiagram
    participant M as Manufacturer
    participant QC as Quality Control
    participant S as Sensors (IoT)
    participant BC as Blockchain Network
    participant D as Distributor
    participant C as Clinic

    M->BC: Log Lysate Processing
    M->BC: Log Purification (UC/Chrom)
    M->BC: Log Multivalent Salt Addition (e.g., 200mM NaPO4, IS 600mM, pH 7.5)
    M->BC: Log Concentration (e.g., 5e13 vg/mL)
    QC->BC: Log DLS & Titer Results (Hashed)
    S->BC: Log Environmental Data (Hashed)
    BC->D: Verifiable Batch Record
    D->BC: Log Storage & Shipping Conditions
    BC->C: Verifiable Product History
    C->BC: Log Receipt & Final Storage
```

5. The "Inverse" or Failure Mode

Derivative 5.1: Reversible Aggregation for Controlled Release

Enabling Description: An rAAV formulation is designed to undergo reversible aggregation, forming stable macro-aggregates at high ionic strength (e.g., 300 mM sodium citrate) and pH 7.8, but disaggregating into monomeric virions upon exposure to a specific trigger. This "trigger" could be a change in ionic strength (e.g., rapid dilution into a low ionic strength physiological buffer, <100 mM), pH (e.g., shift to pH 6.0 within an endosome), or the presence of a specific cleavable polymer linker (e.g., a PEG-based crosslinker that degrades in response to a protease or light). The rAAV virions are purified and concentrated as per the parent patent to 4.0x10^13 vg/mL. The formulation then incorporates a reversibly aggregating multivalent salt complex (e.g., dicalcium phosphate with a weakly chelating agent) that allows for controlled aggregation and subsequent disaggregation, enabling localized storage or targeted release post-administration while minimizing systemic immunogenicity of aggregates.
```
stateDiagram-v2
    [*] --> Purified_rAAV
    Purified_rAAV --> Formulation_Reversible_Aggregate: (300mM Citrate, pH 7.8 + Dicalcium Phosphate/Chelator)
    Formulation_Reversible_Aggregate --> Stable_MacroAggregate
    Stable_MacroAggregate --> Trigger_Applied: (Dilution, pH Change, Enzyme/Light)
    Trigger_Applied --> Disaggregation: (into Monomeric Virions)
    Disaggregation --> Controlled_Release
    Controlled_Release --> [*]
```

Derivative 5.2: Low-Power, Limited-Functionality Storage for Emergency Transport

Enabling Description: A compact, low-power rAAV storage system is developed for emergency or field transport, prioritizing short-term stability over optimal long-term preservation. Purified rAAV virions at a concentration of 2.0x10^13 vg/mL are formulated with a minimum effective ionic strength of 180 mM using a simpler salt blend of 50 mM magnesium sulfate and 40 mM sodium phosphate at pH 7.6. This formulation provides sufficient stability against immediate aggregation (e.g., for 24-48 hours at ambient temperature) but may experience gradual infectivity loss or minor aggregation over longer periods or under repeated stress. The transport container includes minimal active cooling (e.g., Peltier elements powered by a small battery) to maintain temperatures below 25°C, sacrificing deep-freeze capability for portability and reduced energy consumption. A simple indicator (e.g., a turbidity sensor or colorimetric assay) provides a "go/no-go" assessment of aggregation status without requiring complex DLS equipment.
```
graph TD
    A[Purified rAAV Virions (2e13 vg/mL)] --> B{Formulation: (50mM MgSO4 + 40mM NaPO4, pH 7.6, IS 180mM)}
    B --> C[Emergency Transport Container]
    C -- "Limited Cooling (Peltier, <25C)" --> D(Short-term Stability (24-48h))
    C -- "Turbidity/Colorimetric Sensor" --> E[Go/No-Go Aggregation Indicator]
    D --> F[Field Use / Temporary Storage]
```

Derivative 5.3: Integrated "Sentinel" Virions for Predictive Aggregation Detection

Enabling Description: In this derivative, a small, non-functional subset of "sentinel" rAAV virions is introduced into the active rAAV preparation. These sentinel virions are engineered (e.g., surface-modified with fluorescent tags or slightly altered capsid proteins) to exhibit a higher propensity for aggregation than the therapeutic virions, under sub-optimal conditions. The formulation contains 100 mM sodium sulfate to provide an ionic strength of 300 mM at pH 7.7. When aggregation conditions begin to emerge (e.g., due to temperature fluctuation, pH drift, or mechanical stress), the sentinel virions aggregate first. An inline optical sensor (e.g., based on fluorescence correlation spectroscopy or simple light scattering) specifically detects the aggregation of these sentinel virions, providing an early warning signal of impending instability in the therapeutic batch before it affects the primary product. This allows for proactive corrective measures or quarantine of the batch.
```
flowchart TD
    A[Purified rAAV Virions] --> B(Mixing Chamber)
    C[Multivalent Salts (100mM Na2SO4, IS 300mM, pH 7.7)] --> B
    D[Engineered Sentinel Virions] --> B
    B --> E[Formulated rAAV + Sentinels]
    E --> F(Inline Optical Sensor)
    F -- "Detects Sentinel Aggregation" --> G{Early Warning System}
    G -- "Alerts/Intervention" --> H[Quality Control]
```

Combination Prior Art Scenarios

US7704721 (High Ionic Strength AAV Formulation) + Open-Source Chromatography Software (e.g., OpenChrom™):
- Description: The methods of purifying rAAV virions described in US7704721 (specifically, column chromatography, Method 2 from Example 1) are integrated with an open-source chromatography data system like OpenChrom™. This combination allows for precise control, data acquisition, and analysis of chromatographic purification steps (e.g., cation exchange chromatography with Poros HS50 resin) before the addition of multivalent salts. OpenChrom™ can manage gradients, monitor UV absorbance, and track fraction collection, optimizing the initial purification efficiency to yield high-purity rAAV virions that are then formulated using the high ionic strength solutions of US7704721. The open-source nature of the software provides a readily accessible platform for implementing and further developing these integrated purification and formulation strategies.
US7704721 (High Ionic Strength AAV Formulation) + Open-Source Dynamic Light Scattering (DLS) Device (e.g., DIY DLS with Arduino/Raspberry Pi):
- Description: The aggregation assessment method of US7704721, which relies on Dynamic Light Scattering (DLS) to measure average particle radius (Rh), is combined with a low-cost, open-source DLS device. Such a device, built using readily available components and programmed with open-source software (e.g., Python libraries on an Arduino or Raspberry Pi), can perform DLS measurements on rAAV preparations. This allows for real-time or rapid batch analysis to confirm that the high ionic strength formulation (e.g., 100 mM sodium citrate, 10 mM Tris, pH 8.0) effectively maintains Rh values below 20 nm, as taught by the patent. This combination democratizes the quality control aspect of rAAV formulation, making the assessment of aggregation in high ionic strength solutions widely accessible and obvious to those skilled in the art.
US7704721 (High Ionic Strength AAV Formulation) + Open-Source Laboratory Information Management System (LIMS) (e.g., Open LIMS):
- Description: The entire process described in US7704721, from lysate preparation, through rAAV purification (e.g., Method 1 using double CsCl gradient ultracentrifugation), nuclease treatment (Claim 2), and final high ionic strength formulation (e.g., with 300 mM sodium phosphate at pH 7.5), is managed and tracked using an open-source Laboratory Information Management System (LIMS) like Open LIMS. This LIMS records all experimental parameters, reagent lots (including specific multivalent salts like sodium citrate or magnesium sulfate), instrument calibration data, and results from quality control assays (e.g., PCR for vg/mL quantification, infectivity titer assays, DLS measurements). The integration ensures a comprehensive, auditable data trail for each rAAV batch produced with the aggregation-preventing formulations, making the standardized management of such a process a matter of routine laboratory practice.